Budesonide/Formoterol

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary DiseaseEmphysemaBronchiolitis Obliterans

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

Budesonide/Formoterol

AstraZeneca

Approved

162

Singulair

AstraZeneca

Preclinical

173

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

354

Spiriva

Boehringer Ingelheim

Preclinical

85

Formoterol Fumarate

AstraZeneca

Preclinical

86

Blood Withdrawn

Emergent BioSolutions

Preclinical

17

Lexapro

SShirley Ryan AbilityLab

Preclinical

18

Allergen Immunotherapy Extract

JJohns Hopkins University

Preclinical

19

Inhaled Corticosteroids

Boehringer Ingelheim

Preclinical

610

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1Show 5 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Asthma16 trials

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients

Completed·AstraZeneca·Phase 3·NCT00252785·340 enrolled

Titratable Dosing in Moderate to Severe Asthmatics

Completed·AstraZeneca·Phase 3·NCT00651768·570 enrolled

Ventilation and Perfusion in Asthmatics

Not yet recruiting·UUniversity of Miami·Phase 4·NCT07426458·40 enrolled

Show 13 more trials

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

Terminated·—·Phase 4·NCT01070888·6 enrolled

Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma

Completed·AstraZeneca·Phase 3·NCT00255255·120 enrolled

Prevention of Asthma Relapse After Discharge From Emergency

Completed·AstraZeneca·Phase 3·NCT00326053·600 enrolled

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting·GGelb, Arthur F., M.D.··NCT00576069·60 enrolled

Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients

Completed·AstraZeneca·Phase 2·NCT00989833·66 enrolled

Symbicort in Asthmatic Children - SEEDLING

Completed·AstraZeneca·Phase 3·NCT00651547·405 enrolled

SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma

Completed·AstraZeneca·Phase 3·NCT00290264·1,000 enrolled

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

Completed·AstraZeneca·Phase 3·NCT00319306·550 enrolled

The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04171180·500 enrolled

SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma

Completed·AstraZeneca·Phase 3·NCT00288379·16 enrolled

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Completed·HHat Yai Medical Education Center·Phase 3·NCT02725242·77 enrolled

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

Completed·AstraZeneca·Phase 3·NCT00646529·175 enrolled

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Active, not recruiting·Sanofi·Phase 2·NCT06676319·556 enrolled

Chronic Obstructive Pulmonary Disease6 trials

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 3·NCT02345161·1,811 enrolled

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 4·NCT03478696·732 enrolled

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 4·NCT03478683·729 enrolled

Show 3 more trials

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Completed·NNational Jewish Health·Phase 4·NCT01253473·46 enrolled

Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed·AstraZeneca·Phase 4·NCT01397890·793 enrolled

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed·AstraZeneca·Phase 3·NCT01069289·1,293 enrolled

Efficacy3 trials

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

Completed·AstraZeneca·Phase 3·NCT00651651·450 enrolled

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Completed·AstraZeneca·Phase 3·NCT00652002·450 enrolled

Efficacy of SLITone in House Dust Mite Allergic Patients

Completed·AALK-Abelló A/S·Phase 2/3·NCT00633919·124 enrolled

PMD2 trials

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

Completed·AstraZeneca·Phase 2·NCT00658255·175 enrolled

Gemini Symbicort pMDI

Completed·AstraZeneca·Phase 3·NCT00646516·615 enrolled

Adolescent2 trials

Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM

Completed·AstraZeneca·Phase 3·NCT00652392·750 enrolled

Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Completed·AstraZeneca·Phase 3·NCT00646321·540 enrolled

11 more indications

Local1 trial

Local Phase 4 Pan-European SMART Study

Completed·AstraZeneca·Phase 4·NCT00463866·8,424 enrolled

LAM1 trial

Anti-Inflammatory Reliever South Africa

Recruiting·UUniversity of KwaZulu·Phase 3·NCT06429475·1,038 enrolled

Prednisolone1 trial

Comparison Between Symbicort® and Prednisolone in COPD

Completed·AstraZeneca·Phase 3·NCT00259779·120 enrolled

Absorption1 trial

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Completed·Orion Corporation, Orion Pharma·Phase 1·NCT03073057·20 enrolled

Cardiovascular1 trial

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Completed·UUniversity of Alberta·Phase 1·NCT06027606·81 enrolled

SARS CoV 2 Infection1 trial

Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

Not yet recruiting·HHuashan Hospital·N/A·NCT06597682·632 enrolled

Emphysema1 trial

Effect of Symbicort on Sleep Quality in Patients With Emphysema

Unknown status·TTemple University·Phase 3·NCT01602523·40 enrolled

Air Pollution1 trial

Salvational Intervention for Reducing AECOPD Under Severe Air Pollution

Completed·PPeking University First Hospital·N/A·NCT03083067·402 enrolled

Bronchiolitis Obliterans1 trial

Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01560689·32 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Completed·AstraZeneca·Phase 3·NCT00421122·315 enrolled

Unspecified3 trials

Symbicort Onset of Action 2

Completed·AstraZeneca·Phase 3·NCT00646009·48 enrolled

Symbicort Onset of Action 1

Completed·AstraZeneca·Phase 3·NCT00646620·48 enrolled

Atlantis Symbicort

Completed·AstraZeneca·Phase 3·NCT00646594·1,200 enrolled

Details

Drug Info

Related News